Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06053658 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

A Phase 2 study of Renal Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
48
Enrollment target
5
Study locations

NCT06053658: Recruiting Phase 2 study of Renal Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.

NCT06053658 is a Phase 2 study of Renal Cell Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 48 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (80% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06053658, a Phase 2 study of Renal Cell Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
48 participants
Enrollment target
5
Study locations

Study Summary

To learn if giving tivozanib in combination with nivolumab can help to control advanced nccRCC.

Conditions Studied

Renal Cell Carcinoma

Interventions

  • DRUG Nivolumab
  • DRUG Tivozanib

Study Locations (5)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston

Texas

  • UT Southwestern Medical Center - Dallas
  • M D Anderson Cancer Center - Houston

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2024-01-05
Est. Completion 2028-11-01
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What NCT06053658 shows while recruiting

NCT06053658 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (80% lower).

The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.

NCT06053658 lists 5 locations in 3 states (Massachusetts, Texas, Michigan).

Frequently Asked Questions

What is clinical trial NCT06053658 about?

NCT06053658 is a clinical study titled "Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma". To learn if giving tivozanib in combination with nivolumab can help to control advanced nccRCC.

What is the current status of trial NCT06053658?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2024-01-05. Estimated completion is 2028-11-01.

What conditions does trial NCT06053658 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma.

What interventions are being tested in trial NCT06053658?

The interventions under investigation include: Nivolumab (DRUG), Tivozanib (DRUG).

Who is sponsoring clinical trial NCT06053658?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06053658 being conducted?

This trial has 5 study locations across Massachusetts, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06053658's enrollment target sits among peer trials

48 80th of 121 higher than 41 of 121 other Renal Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06053658

Source: ClinicalTrials.gov NCT06053658, the US trial registry maintained by the National Library of Medicine. NCT06053658 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.